跳至: [中文]   [數字0-9]   [ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z ] 請輸入前幾個字:

顯示項目331-340 / 12927. (共1293頁) << < 29 30 31 32 33 34 35 36 37 38 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2015-07-28	A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms	Scientific Reports. 2015 Jul 28;5:Article number 12578.
2023-08-16	A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine	Emerging Microbes and Infections. 2023 Aug 16;12(2):Article number 2249130.
2017-09	A tolerance interval approach to assessing the biosimilarity of follow-on biologics	Statistics in Biopharmaceutical Research. 2017 Sep;9(3):286-292.
2016-05	A toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population	Oncotarget. 2016 May;7(21):30804-30819.
2019-07-31	A Tri-fusion reporter mouse reveals tissue-specific FGF1B promoter activity in vivo	Scientific Reports. 2019 Jul 31;9:Article number 11143.
2022-08-16	A tumor accelerator based on multicomponent bone scaffolds and cancer cell homing	Polymers. 2022 Aug 16;14(16):Article number 3340.
2021-12	A user-friendly objective prediction model in predicting colorectal cancer based on 234 044 Asian adults in a prospective cohort	ESMO Open. 2021 Dec;6(6):Article number 100288.
2018-09-14	AAV serotype 8-mediated liver specific GNMT expression delays progression of hepatocellular carcinoma and prevents carbon tetrachloride-induced liver damage	Scientific Reports. 2018 Sep 14;8:Article number 13802.
2011-04	ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment	Pharmacogenetics and Genomics. 2011 Apr;21(4):163-170.
2016-06	ABCG2 overexpression confers poor outcomes in hepatocellular carcinoma of elderly patients	Anticancer Research. 2016 Jun;36(6):2983-2988.

顯示項目331-340 / 12927. (共1293頁) << < 29 30 31 32 33 34 35 36 37 38 > >> 每頁顯示[10|25|50]項目